#drreddys
Read the highlights from the IGNITE Educational Meeting on Immunotherapy and the Evolving Management of Nasopharyngeal Carcinoma | Read here: t.ly/UXOV9 #NasopharyngealCarcinoma #DrReddys #DannyRischin #OncologyNews #IndustrySpotlight #MedEd #Heath #CancerResearch #MedSky #CanSky #OncSky
June 30, 2026 at 12:45 AM
Web Server Hosting Dr Reddy’s Shares Slide 6% After Canada Flags Semaglutide Compliance Issue Arise Server #DrReddys #Semaglutide #PharmaNews #StockMarket #Investing
Dr Reddy’s Shares Slide 6% After Canada Flags Semaglutide Compliance Issue
Shares of Dr Reddy's hit a five-month low as analysts said that the recent development can delay the launch of its new injection
dlvr.it
October 30, 2025 at 7:09 AM
🌏 Sleepless nights in focus! The Asia-Pacific Insomnia Market is booming with rising stress & tech lifestyle.
Top contributors:
🔹 @TakedaPharma
🔹 @SunPharma_Live
🔹 @DrReddys

#SleepCare #MentalHealthAsia #Pharma #Healthcare #MRFR #AsiaMarket

www.marketresearchfuture.com/reports/asia...
Asia Pacific Insomnia Market Size, Share, Growth Report 2032
Asia Pacific Insomnia Market growth is projected to reach USD 0.20 Billion, at a 8.12% CAGR by driving industry size, share, top company analysis, segments research, trends and forecast report 2024 to...
www.marketresearchfuture.com
October 8, 2025 at 7:45 AM
With up to 50% of their revenues tied to US sales, Indian #pharma#industry braces for impact as the White House accelerates domestic production plans. #sunpharma #cipla #lupin #drreddys #zydus #trump
www.policycircle.org/industry/ind...
India’s pharma industry faces heat from Trump’s reshoring drive | Policy Circle
With up to 50% of their revenues tied to US sales, Indian pharma industry braces for impact as the White House accelerates domestic production plans. #US #Trump #pharma
www.policycircle.org
May 8, 2025 at 3:09 AM
March 16, 2025 at 9:00 PM
📰 Dr. Reddy’s Laboratories Recruits Sensory Scientist to Expand Food Tech Capabilities

https://pneumetron.com/news/technology/dr-reddys-laboratories-recruits-sensory-scientist-93ea0f

#DrReddys #FoodTech #BiotechJobs #SensoryScience
August 10, 2026 at 9:43 AM
Web Server Hosting Dr Reddy's, Aurobindo, Cipla: Pharma Stocks To Remain In Focus Today After Trump's New Generic Drugs Tariff Plan Arise Server #PharmaStocks #GenericDrugs #TrumpTariff #DrReddys #Aurobindo
Dr Reddy's, Aurobindo, Cipla: Pharma Stocks To Remain In Focus Today After Trump's New Generic Drugs Tariff Plan
Imported generic medicines will remain tariff-free for two years from August 1, after which the US plans to impose a 100% duty for one year and a 200% tariff thereafter.
dlvr.it
July 22, 2026 at 3:27 AM
🏥 U.S. FDA has raised seven observations during an inspection of Dr. Reddy’s biologics facility in Hyderabad.

Read the full story: dw24news.com/u-s-fda-rais...

#DrReddys #USFDA #PharmaNews #Hyderabad #DW24News
U.S. FDA Raises Seven Observations at Dr. Reddy’s Biologics Facility in Hyderabad - DW24 News
In a recent development, the U.S. Food and Drug Administration (FDA) has identified seven observatio
dw24news.com
June 26, 2026 at 10:53 AM
Did you see this, @Dereklowe? "we developed a novel synthesis route for the #Covid-19 drug #Paxlovid/Nirmatrelvir, which was able to reduce the synthesis time by more than 30 fold (30-60 min compared to 16-18 hours for a traditional batch process)" @AurigeneDiscov @drreddys
November 19, 2024 at 2:28 PM
April 3, 2025 at 3:08 PM
Dr. Reddy’s Laboratories: USFDA completes GMP inspection at API facility (CTO-2) in Bollaram, Hyderabad (Nov 13-19, 2024). Company receives Form 483 with 7 observations.

#DrReddys #USFDA #PharmaNews #GMP
November 19, 2024 at 1:14 PM
Dr. Reddy's Launches First-to-Market Bosutinib Generic in the U.S. Dr. Reddy's launched Bosutinib Tablets 400 mg in the United States, saying the product was first-to-file and...

https://www.narrowit.com/news/dr-reddys-bosutinib-generic-launch-2026-06-13
#DrReddyS #RDY #Bosutinib #GenericDrugs
Dr. Reddy's launches first-to-market U.S. Bosutinib 400 mg generic | Narrowit.com
Dr. Reddy's launched Bosutinib Tablets 400 mg, a generic equivalent of Bosulif, in the United States with 180-day exclusivity eligibility for the strength.
www.narrowit.com
June 13, 2026 at 4:19 PM